Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
暂无分享,去创建一个
S. Mandrekar | D. Gandara | A. Adjei | K. Rowland | A. Adjei | G. Dy | S. Schild | J. Molina | R. Zinner | P. Stella | K. L. Ziegler